All studies
RecruitingPHASE1INTERVENTIONAL

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

This research is looking at a new medicine called ALN-5288 for individuals living with Alzheimer's disease. The main goal is to find out if the medicine is safe and well-tolerated when given directly into the fluid around the brain and spinal cord. Researchers will also be observing how the medicine works in the body and if it has any effects on the disease itself. To understand this properly, some participants will receive the active study medicine, while others will be given a placebo, which looks like the medicine but contains no active drug. This helps scientists compare the effects fairly. Participants will be aged between 40 and 80 and have a diagnosis of Alzheimer's.

At a glance

Status
Recruiting
Phase
PHASE1
Sponsor
Alnylam Pharmaceuticals
Enrolment target
50
Start
15 Oct 2025
Estimated completion
06 Mar 2030

What is this study about?

This study is a research project designed to learn more about a new medicine called ALN-5288 for people with Alzheimer's disease. Alzheimer's is a condition that affects memory, thinking, and daily activities. The medicine is given into the fluid that surrounds your brain and spinal cord, similar to an injection you might get for a spinal tap.

The main aim of this study is to check if ALN-5288 is safe and if your body can handle it well. We also want to understand how your body processes the medicine and what effects it might have on the disease. By taking part, you would be helping doctors and scientists learn more about new ways to treat Alzheimer's, which could help many other people in the future.

It's important to remember that this is a very early-stage study (called Phase 1). This means it's one of the first times this medicine is being tested in humans. Because of this, we don't yet know if the medicine will be effective, but understanding its safety is a crucial first step.

Key takeaways

  • This study is for a new medicine (ALN-5288) for Alzheimer's disease.
  • The main goal is to check for safety and how the medicine works in the body.
  • Participants will receive the medicine or a placebo via spinal injection.
  • You must be 40-80 years old with an Alzheimer's diagnosis to join.
  • Close medical monitoring will be provided throughout the study.
  • Participation is voluntary, and you can withdraw at any time.

Who may be eligible?

To join this study, you would generally need to be between 40 and 80 years old and have a diagnosis of Alzheimer's disease. This diagnosis needs to be supported by special tests, like certain brain scans or checks of your spinal fluid, and confirmed within the last 7 years. You should also have mild memory problems or dementia linked to Alzheimer's.

There are also some important reasons why someone might not be able to join. For example, if your memory problems are caused by a different kind of dementia, or if you have certain health conditions like severe high blood pressure, uncontrolled seizures, or particular heart, liver, or kidney problems. You also wouldn't be able to join if you have certain infections like HIV or hepatitis.

Finally, if you have other serious mental health conditions that aren't well controlled, or if you have problems with your brain or spine that would make injections into that area difficult, you would not be able to participate. The study team will check all these things carefully to make sure it's safe for you to take part.

Quick self-check
  • Are you between 40 and 80 years old?
  • Do you have a diagnosis of Alzheimer's disease confirmed by special tests?
  • Do you have mild memory problems or dementia related to Alzheimer's?
  • Do you have any serious heart, liver, or kidney problems?
  • Do you have uncontrolled high blood pressure or seizures?
  • Do you have certain infections like HIV or hepatitis?

This is a guide only — the research team will confirm whether you can take part.

What does participation involve?

If you decide to take part in this study, you would receive either the new study medicine, ALN-5288, or a placebo (a dummy medicine with no active drug). This will be given through an injection into the fluid around your spinal cord. The study involves regular visits to the clinic for medical checks, further injections, and to monitor your health and any effects of the medicine. You will have blood tests and other examinations.

The exact number of visits and the full length of your participation would be explained in detail by the study team. They will monitor your health closely throughout the study period. It's important to know that you wouldn't necessarily know whether you are receiving the active drug or the placebo, as this helps ensure the results are accurate and unbiased.

Potential risks and benefits

Potential benefits of taking part could include gaining access to a new experimental medicine for Alzheimer's disease that isn't yet available generally. You would also receive close medical attention and monitoring throughout the study. However, because this is an early-stage study, it's not known if ALN-5288 will help your Alzheimer's symptoms. Potential risks could include side effects from the medicine itself, or discomfort and risks associated with the injections into your spinal fluid. As with all medical procedures, complications can occur, although the study team will take every precaution. You will receive a full explanation of all known and potential risks before you decide to participate, and you are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (13)

  • Clinical Trial Site
    Montreal, Canada· Recruiting
  • Clinical Trial Site
    Ottawa, Canada· Recruiting
  • Clinical Trial Site
    Toronto, Canada· Recruiting
  • Clinical Trial Site
    Toronto, Canada· Not yet recruiting
  • Clinical Trial Site
    's-Hertogenbosch, Netherlands· Not yet recruiting
  • Clinical Trial Site
    Amsterdam, Netherlands· Not yet recruiting
  • Clinical Trial Site
    Barcelona, Spain· Not yet recruiting
  • Clinical Trial Site
    Madrid, Spain· Not yet recruiting
  • Clinical Trial Site
    Sant Cugat del Vallès, Spain· Not yet recruiting
  • Clinical Trial Site
    Glasgow, United Kingdom· Not yet recruiting
  • Clinical Trial Site
    London, United Kingdom· Recruiting
  • Clinical Trial Site
    Sheffield, United Kingdom· Not yet recruiting

+1 more sites — see the official record for the full list.

Common questions

What is ALN-5288?

ALN-5288 is a new medicine being tested for Alzheimer's disease. We are trying to find out if it is safe and how it works in the body.

How will the medicine be given?

The medicine will be given through an injection directly into the fluid around your spinal cord, similar to a spinal tap.

Will I get the real medicine or a dummy medicine?

Some people in the study will get the active medicine, and others will get a placebo (a dummy medicine). This helps us compare the effects fairly, and you won't know which one you are receiving.

How long will I need to be in the study?

The total duration of your participation will be explained by the study team, but it will involve several visits over a period of time.

Can I leave the study at any time?

Yes, you are free to leave the study at any time, for any reason, without it affecting your regular medical care.

How to find out more

Clinical Trial Information Line

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "A Study to Evaluate ALN-5288 in Patients With Alzheimer's Di…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.